Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monza – page 219

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monza at a glance
2 831
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 831 trials in Monza

Open in trial search

Non-small cell lung cancer

Not recruiting

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-4830
  • Sponsor:Merck Sharp & Dohme LLC

Chronic hepatitis B+1

Not recruiting

Study of Bepirovirsen for Patients with Chronic Hepatitis B on Nucleos(t)ide Analogue Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not recruiting

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3116
  • Sponsor:Deciphera Pharmaceuticals Inc.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Not recruiting

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986288
  • Sponsor:Bristol Myers Squibb International Corporation

HIV infection

Not recruiting

Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Non-small cell lung cancer stage IV+1

Not recruiting

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986315
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

K-ras gene mutation

Not recruiting

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

  • NSCLC Treatment Studies
  • Lymphoma Therapy Innovations
  • Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

  • Inflammatory Disease Studies
  • Biomarker Research
  • Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

  • Vaccine Efficacy Studies
  • Long-term Immunity Research
  • Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

  • Preventive Cardiology
  • Hypertension Management
  • Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.